Nelson Peltz's Trian Fund Management said in a letter to shareholders on Wednesday that medical device maker Solventum's separation from 3M has not been living up to its potential.
Solventum's Clarity precision grip attachments enhance treatment outcomes for orthodontic patients, reducing the risk of misplaced and malformed attachments.
Solventum Corporation (NYSE:SOLV ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Kevin Moran - SVP, IR Bryan Hanson - CEO Wayde McMillan - CFO Conference Call Participants Travis Steed - Bank of America Patrick Wood - Morgan Stanley Vik Chopra - Wells Fargo David Roman - Goldman Sachs Rick Wise - Stifel Ryan Zimmerman - BTIG Jason Bednar - Piper Sandler Chris Senyek - Wolfe Research Operator Good afternoon. My name is Amy, and I will be your conference operator for today.
Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products.
3M spin-off Solventum raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products.
SOLV's Q3 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset sales decline.
The business is expected to draw takeover interest from private equity and strategic buyers.
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Watching what the smart money is buying can be a useful investment strategy.
SOLV announces the launch of its V.A.C. Peel and Place Dressing for providing efficient and effective care in case of negative pressure wound therapy.
Jenny Harrington, CEO Gilman Hill Asset Management, joins CNBC's "Halftime Report" to explain why she's getting out of Solventum.